We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mast Therapeutics, Inc. (delisted) | AMEX:MSTX | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.131 | 0 | 01:00:00 |
Currently Enrolling Patients in Phase 3 Sickle Cell Clinical Trial, Phase 2 ALI Clinical Trial Scheduled to Commence in Q1 2014, Acquired Aires Pharmaceuticals, Inc.
SAN FRANCISCO, CA--(Marketwired - Feb 28, 2014) - Vista Partners announced today that it has updated coverage on Mast Therapeutics Inc. (NYSEMKT: MSTX) ("MSTX"), a publicly traded biopharmaceutical company headquartered in San Diego, CA; and maintains its twelve-month price target of $2.25. Ross Silver, Principal Analyst at Vista Partners, stated, "There has been considerable partnership and M&A activity for companies working on Sickle Cell Disease. On Sept. 19th, 2012, Selexys Pharmaceuticals, Corp. entered into an agreement with Novartis Pharmaceuticals, the agreement with Novartis could reach up to $665 million. In October 2011, Pfizer signed a licensing deal with U.S. firm GlycoMimetics which may be worth up to $340 million, including an upfront payment as well as development, regulatory, and commercial milestones, plus royalties." Mr. Silver, concludes, "GlycoMimetics (NASDAQ: GLYC), the first biotech IPO of 2014, currently trades at a market cap of around $225M whereas MSTX is around $85M. GlycoMimetics has only completed a Phase 2 trial whereas MSTX is actively enrolling patients in a Phase 3 trial."
To download a FREE copy of the Mast Therapeutics Inc. research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.
About Vista Partners: Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking.
Please follow Vista Partners on Twitter @VistaPResearch & Facebook at Vista-Partners to receive updates, thoughts and ideas about our coverage universe of companies.
Disclaimer & Disclosure: For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.
Contact: 877.215.4813 Email Contact
1 Year Savara Inc. Chart |
1 Month Savara Inc. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions